Pomegranate Interactions

Pomegranate juice inhibits intestinal CYP3A4, the main enzyme that metabolizes simvastatin, atorvastatin, and lovastatin. A published case report links pomegranate juice consumption to rhabdomyolysis in a patient stable on rosuvastatin, and the same enzyme inhibition can raise the systemic exposure and muscle toxicity risk of CYP3A4-metabolized statins.

Pomegranate polyphenols (pedunculagin, punicalin, gallagic acid) directly inhibit angiotensin-converting enzyme, and clinical trials show pomegranate juice lowers systolic and diastolic blood pressure on its own. Combined with prescription ACE inhibitors the effects can stack, potentially causing additive hypotension, dizziness, or hyperkalemia.

Pomegranate juice contains punicalagins and other polyphenols that inhibit CYP2C9 and CYP3A4 in vitro, which would slow warfarin metabolism. Case reports describe both elevated INR (one patient reached INR 14 after heavy consumption) and subtherapeutic INR after stopping habitual juice intake.